Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at ...

Losing weight can be a challenge for many. With so many variables present in everyday life, including stress, lack of sleep, ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

The agency is due to make a determination on the shortage status of Zepbound by Dec. 19. But another delay could be possible ...

The company also raised its quarterly dividend 15% amid rapid growth fueled in part by the blockbuster weight-loss drug ...

People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...